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ABSTRACT 
An immunoassay in optimised conditions with a highly sensitive surface plasmon resonance 
(SPR) based biosensor was developed for the detection of the cancer biomarker 
carcinoembryonic antigen (CEA). Different formats of the immunoassay were initially 
investigated on the surface of the gold sensor chip. A self-assembled monolayer (SAM) was 
formed on the gold chip using 11-mercaptoundecanoic acid (MUDA), before the 
immobilisation of the antibodies was conducted. The assay was then formed in a direct 
capture and a sandwich assay. In order to increase the sensor signal the CEA antigen was 
incubated with the detection/capture antibody before it was injected to the sensor chip surface 
and the results were recorded in real-time using the Biacore 3000 instrument. A detection 
limit of 3 ng ml
-1
 CEA was obtained with a dynamic detection range from 3 ng ml
-1
 to 400 ng 
ml
-1
 with correlation coefficients of 1.00 and 0.99 for the sandwich and rabbit anti-mouse 
(RAM) capture assay. Kinetic data analysis was performed for the standard capture test and 
subsequently for the developed assays and Rmax showed an increase from 215 RU for the 
standard capture test to 428 RU for the RAM-capture assay and 734 RU for the sandwich 
assay, respectively. The developed SPR immunosensor using the sandwich assay format 
showed high sensitivity and reproducibility for CEA detection which makes it a promising 
procedure for cancer biomarker analysis.  
 
 
 
 
 
 
 
 
Keywords: Carcinoembryonic antigen, Immunoassay, SPR, Early diagnosis of cancer, 
Homogeneous assay. 
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1. Introduction  
Carcinoembryonic antigen (CEA) has been widely studied in clinical analysis as a 
tumour biomarker. CEA is a cell adhesion glycoprotein and is a member of the 
immunoglobulin super family [1]. The protein was first identified from human colon cancer 
tissue extracts in 1965 by Phild Gold and Samuel O. Freedman [2]. CEA is produced during 
foetal development and the production of it terminates before birth. In healthy individuals the 
normal level of CEA is between 3-5 ng ml
-1
 and this level may increase up to 10 ng ml
-1
 due 
to other benign diseases [3]. The protein scarcely exists in the blood of healthy people except 
cigarette-smokers. However, its concentration shows a significant increase in some conditions 
including lung cancer, colorectal carcinoma, pancreatic carcinoma and breast carcinoma [4]. 
Hence, it can be used as a biomarker for diagnosis and prognosis of cancer. CEA levels over 
20 ng ml
-1
 are usually associated with patients with cancer in metastatic state [5].     
The treatment of lung cancer is a long and difficult process and the survival scarcely 
reaches 5 years. The most crucial point for the best result is to diagnose the disease at an early 
stage. To this aim, many methods are now available to diagnose the disease including chest x-
ray, computerised tomography, magnetic resonance imaging, positron emission tomography, 
sputum cytology and biopsy. However, some of these methods are not suitable for all patients 
due to the other pathologies they may have [6]. Moreover, patients can often experience great 
pain and complications because of some diagnostic tools such as biopsy. Since the current 
diagnostic methods are also time consuming, a new sensitive and rapid method is necessary 
for both lung and colon cancers detection. CEA is one of the most investigated tumour 
markers in certain cancers [7], with several clinical and research-based applications [8]. 
However, due to the absence of both rapid and sensitive diagnostic tool, CEA related cancers 
cannot be detected at an early stage which is vital for successful treatment. Therefore, 
biosensor technologies can play a crucial role in achieving this aim [9, 10]. Though enzyme-
linked immunoassay (ELISA) has been generally used for both clinical and research field, the 
SPR-based biosensors will provide label-free and real-time detection system [11].  SPR based 
biosensors  have  also been used for  other  diseases which occur at very high incidence level 
using  genetic [12] or protein markers [13]  which exist in either tissue or body fluids or in 
both [14]. 
In the present paper we report on the development of a surface plasmon resonance 
(SPR) based biosensor platform for the detection of CEA, the most crucial tumour marker for 
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lung and colon carcinomas. An immunoassay for CEA was developed and optimised on the 
SPR gold sensor surface to achieve high sensitivity for a real-time disease diagnosis.  
Different homogeneous assay formats were investigated including capture and sandwich 
immunoassay. By using this label-free real-time biosensor technology we were able to 
achieve a low detection limit for CEA which represents the critical CEA level in non-smoker 
individuals. This will help in the identification of possible cancer patient. The technique 
shows a promising future technology for the diagnosis of cancer at inchoate stage without the 
use of invasive surgical procedures.   
 
2. Material and Methods 
2.1. Materials and reagents 
Phosphate buffered saline (PBS, 0.01 M phosphate buffer, 0.0027 M potassium chloride and 
0.137 M sodium chloride, pH 7.4), bovine serum albumin (BSA), N-hydroxysuccinimide 
(NHS), ethanolamine, Human CEA (cat no. C4835) and its monoclonal antibody (C2331) 
were purchased from Sigma Aldrich (Poole, UK). 1-ethyl-3-(3 dimethylaminopropyl)-
carbodiimide (EDC) was purchased from Pierce-Thermo Scientific (Cramblington, UK). 
Mouse monoclonal antibody to carcinoembryonic antigen (CEA) (cat no. ab10037) and 
Mouse Monoclonal (1C11) to cardiac Troponin T: ab8295 was purchased from Abcam 
(Cambridge, UK), monoclonal PSA detection antibody (cat no: MCA2561) obtained from 
AbD Serotec (Kidlington, UK). Mouse IgG (cat no. 015-000-003) and rabbit anti-mouse IgG 
(RAM) was bought from Stratech Scientific Ltd./Jackson ImmunoResearch(Newmarket, UK). 
In the developed sandwich and RAM-capture assays, Sigma anti-CEA antibody (C2331) was 
used as the detection antibody to perform the assay. All other chemicals were of analytical 
grade. 
 
2.2. Instrumentations 
A fully automated SPR-based Biacore 3000 biosensor and the bare gold sensor chips were 
supplied by Biacore GE Healthcare (Uppsala, Sweden). The sensor possesses four sensing 
spots that provide four separate areas for different assay simultaneously. In the current study 
two sensing spots were employed for sandwich and indirect assay formats while the third spot 
provided the control surface. The operating temperature of the assays was 25 °C and the flow 
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rate of the buffer was 10 µl min
−1
 throughout the assay. The data presented in this work are 
the averages of 3 data points for the assays described unless otherwise stated.  
 
2.3. Sensor chip cleaning and MUDA coating 
Bare gold sensor chips were first cleaned using nitrogen plasma for one minute and then 
coated with self assembled monolayer (SAM) by immersing the sensors in 2 mM solution of  
11-mercaptoundecanoic acid (MUDA) overnight followed by rinsing with ethanol and Milli-
Q water and then dried under nitrogen. The SPR sensor chips were then stored at 4 
o
C until 
used.  
 
2.4. Control surface selection 
For the selection of the best control sensor surface, three different antibodies (mouse IgG, 
anti-PSA and anti-troponin produced in mouse) were examined. Since the samples were 
prepared using 5 µg ml
-1
 BSA in all experiments, 300 ng ml
-1 
CEA was diluted in BSA and 
the non-specific binding of this solution to each control surface was measured. A high 
concentration of CEA antigen was used in this confirmation study and the non-specific 
binding of the antigen to each control surface was recorded during the SPR assay.  
 
2.5. Immobilisation of antibodies 
The SAM coated sensor chip was first docked to the Biacore instrument and primed with 
running buffer (10 mM PBS, pH 7.4, 0.0027 M potassium chloride, 0.137 M sodium chloride) 
at a flow rate of 10  µl min
-1
. Monoclonal mouse anti-CEA antibody was then immobilised 
via one flow path of the instrument for the sandwich assay whereas rabbit anti-mouse and 
mouse IgG antibodies (control antibody) were immobilized to the second and third sensor 
array of the chip, to conduct the capture assay and obtain control surface, respectively. The 
immobilisation stage of the immunoassay was obtained using conventional amine coupling 
chemistry. The running buffer in this stage was degassed phosphate buffered saline (PBS). 
During the immobilisation step firstly the sensor chip surfaces were activated with a mixture 
of 400 mM EDC and 100 mM NHS (1:1). Both reagents were prepared in deionised water and 
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immediately mixed before use. EDC-NHS was injected onto the four sensor surfaces 
simultaneously for 3 min (30 µl) to activate the sensor chip surface. Then, 30 µg ml
-1
 coating 
antibodies (anti-CEA antibodies, rabbit anti-mouse and mouse IgG) prepared in 10 mM 
sodium acetate buffer (pH: 5.5) were immobilized to the sensor surfaces. After antibody 
immobilisation, the sensor surfaces were blocked with 30 µg ml
-1
 BSA in PBS buffer for 3 
min (30 µl). Finally, 1 M ethanolamine (pH: 8.5) was used to cap the non-reacted NHS esters 
exist on the sensor surface for 3 min (30 µl). The RU changes were recorded two minutes 
after the protein injection was completed.  
 
2.6. CEA detection 
First assays were performed using direct assay approach without incubation. To increase the 
signal amplification the homogeneous assay was then applied as sandwich and capture 
methods with an incubation step added before the assay taking place in the instrument. 
Different incubation methods were examined, including water bath at 37 °C and with/without 
shaker at room temperature applied prior to the assay. The CEA and detection antibody were 
incubated in the 1.5 ml Eppendorf tube for each concentration of the antigen. The detection 
antibody concentration was chosen as always higher than CEA to prevent any free CEA in the 
solution that can interfere with the binding results. The incubation conditions were then 
optimized as time, temperature and detection/capture antibody concentration. The best results 
were achieved through applying incubation at room temperature for 2 hours using a shaker. 
PBS buffer was used as the running buffer during the CEA marker detection and 5 µg ml
-1
 
BSA in PBS was used to prepare the CEA samples. For the sandwich assay, two different 
mouse anti-CEA antibodies (a coating and detection antibodies) were used while rabbit anti-
mouse (RAM) was preferred as coating antibody for the capture assay. RAM-capture assay is 
an indirect assay here in which RAM was used to capture either mouse anti-CEA antibody or 
CEA bound mouse anti-CEA antibody. The sensor signal difference due to the mass 
difference of free or antigen (CEA) bound anti-CEA antibody was investigated to obtain the 
results. The anti-CEA captured on RAM causes an SPR signal, however the SPR signal is 
higher (due to higher mass) when antigen bound anti-CEA antibody is captured on RAM 
immobilised surface. By subtracting the two responses the affect of antigen to the assay can 
be calculated. Before samples injection, 5µg ml
-1
 BSA and anti-CEA detection antibody were 
injected to all sensor surfaces as negative controls in the experiments. Each CEA sample and 
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negative controls were injected onto the sensor surface for 3 minutes and RU changes were 
recorded. After each binding step the sensor chip surface was regenerated by injecting 100 
mM HCI (1 min, 10 µl) and additional 20 mM NaOH (1 min, 10 µl) where these were found 
to give the best sensor surface regeneration without hindering the affinity of the immobilised 
antibody. All the data points presented are the averages of the triplet measurements unless 
otherwise stated. The limit of detection (LOD) was calculated as the signal obtained from the 
CEA concentration that is equivalent to the 3 times the standard deviation of the signals 
obtained from the blank standards. 
 
3. Results and Discussions 
In this study an SPR based assay for the detection of human CEA tumour marker was 
developed and optimised using different immunoassay formats constructed on the surface of a 
Biacore bare gold sensor chip including a standard capture, rabbit anti-mouse (RAM) capture 
and sandwich assays.  
3.1. Assay optimisation 
Bare gold SPR sensor chips were employed in this work as the sensor platform for the CEA 
detection. Each chip consists of four sensing arrays. The modification of the chips using self -
assembled monolayer’s (SAM) was carried out on the sensor surface. The SAM coated sensor 
chip was first docked to the Biacore instrument and primed with running buffer using a flow 
rate of 10 µl min
-1
. To eliminate non-specific binding to the control sensor array surface, 
control surface selection study was conducted. Three different antibodies (mouse IgG, anti-
PSA and anti-troponin) were investigated and used in this study. The antibodies were 
immobilized to the three different sensor arrays on the Biacore chip using different flow 
channels of the sensor respectively with conventional EDC-NHS chemistry [15]. A 3 minutes 
injection of the antibodies was sufficient to achieve the signal with concentration of 30 µg ml
-
1
 antibody saturation. A 300 ng ml
-1 
CEA solution in PBS buffer containing 5 µg ml
-1
 BSA 
was then injected to all immobilised control surfaces on the sensor array. In addition to the 
CEA, a 5 µg ml
-1
 BSA solution was also examined in a separate experiment in order to 
measure the non-specific binding caused by this solution alone. The recorded RU change for 
non-specific BSA binding was 1±1 RU for anti-PSA and anti-troponin immobilized surface 
while it was 1±0.5 for mouse IgG. Moreover, non-specific binding of the CEA antigen against 
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each surface was observed at zero level and therefore mouse IgG was selected as the control 
surface for further experiments (Figure 1A).  
 
A standard direct assay format in which the coating anti-CEA antibody was immobilized onto 
the active sensor surface and mouse IgG immobilised to the control surface was then 
developed. CEA antigen was then injected on the sensor surface in the concentration range of 
100-400 ng ml
-1
. Though a clear difference was observed between the active sensor surface 
and the control surface, the obtained results were low despite the high concentration of CEA 
used in the test (Figure 1B). The recorded response changes were 258 ± 19 RU using the 
standard direct assay for the binding of 300 ng ml
-1
 CEA. These preliminary tests with high 
concentrations of CEA showed that the direct detection of CEA biomarker using the SPR 
sensor may  not be suitable for the measurement of low CEA concentrations. This was 
confirmed when the optimised direct assay conditions were then applied for the detection of 
lower CEA concentrations (down to 100 ng ml
-1
) achieving a low and irreproducible signal.  
Kinetic data analysis was performed for this assay results and the data was fitted to 1:1 
Langmuir binding model to determine the binding association and dissociation rates [16]. 
With this binding model, KA, KD, Rmax values were calculated as 1.13 x 10
8 
M
-1
s
-1
, 8.8 x 10
-
9
M and 215 RU for the concentration of 300 ng ml
-1
 CEA (using Abcam antibodies in a direct 
affinity assay) (Table 1). Due to the weak responses with the direct assay, other assay formats 
were then investigated. 
 
A sandwich  and RAM-capture assays were then developed under optimised conditions that 
gave much higher response when compared to the standard capture assay. Langmuir binding 
model was also performed for the optimised assays in the linear dynamic range of 3-400 ng 
ml
-1 
of CEA and the results are reported in Table 1. The developed assays provided higher 
responses than the standard direct assay format using Rabbit anti-mouse and Abcam anti-CEA 
antibody as the surface capture antibodies and in both assays the anti-CEA antibody (Sigma) 
was employed as the detection antibody.  
To enhance the sensor signal and improve the sensitivity of the assay further an incubation 
step was introduced where the detection anti-CEA antibody (from Sigma) was incubated first 
with CEA antigen in buffer before the sample was applied to the sensor surface. To optimise 
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this step various incubation procedures were examined including temperature (37 °C, or 22 °C 
and with/out shaking conditions). Optimal results were achieved when a 22 °C with a shaker 
incubator was used.  The principle of the applied homogenous assays (RAM-capture and 
sandwich assays) are shown in Figure 2.  
 
The concentration of the anti-CEA detection antibody used in the assay was also optimised. 
Various concentrations of detection antibody in the range of 1-5 µg ml
-1 
were examined using 
CEA sample concentration range of 50-400 ng ml
-1
. Optimal results were achieved when 5 µg 
ml
-1 
detection antibody was used. Higher concentrations of anti-CEA detection antibody were 
also tested but did not give higher responses.  The time of incubation between the detection 
antibody and the CEA before injecting on the sensor surface was then optimised under these 
conditions to achieve maximum sensitivity.  The RU responses were measured throughout 5 
hours and the highest RU changes were recorded in the first 2 hours of incubation; however, 
the obtained RU changes for each CEA concentration showed gradual decrease after 2 hours 
as depicted in Figure 3. However, it must be noted that these samples did not contain 
preservatives or protein stabilisers. After obtaining these results the assays were performed 
using 1 or 2-hour incubation to observe the difference; however, the recorded RU changes 
were similar in both incubation periods (data not shown for 1 h). Therefore, 1 hour incubation 
was preferred to perform the assay at ambient temperature on a shaker in order to minimise 
the total assay time. This incubation step was performed prior to the measurement of CEA 
binding on the Biacore 3000 biosensor. 
 
3.2. Sandwich and RAM-capture assays characterisation 
In the development of the immunoassay on the sensor chip, three different antibodies were 
used and these included; monoclonal mouse anti-CEA antibody (from Abcam), rabbit anti-
mouse and mouse IgG. The antibodies were immobilised through the separate flow paths of 
the three arrays on the sensor platform. Anti-CEA monoclonal antibodies and rabbit anti-
mouse antibodies were used as the coating antibody for the sandwich and RAM-capture 
assays respectively, whereas mouse IgG provided the control surface.  
The immobilization signal of each antibody was measured during a 3 minutes duration and 
the evaluated RU changes for the immobilization reaction were recorded as 3500 ± 95 for 
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anti-CEA (Abcam), 3000 ± 120 for rabbit anti-mouse and 2800 ± 37.6 for mouse IgG 
antibodies respectively (Figure 4A). A 3 minutes injection of antibodies was sufficient for the 
signal to reach equilibrium; therefore, the immobilisation time was kept at 3 minutes for the 
assay. Although the RU changes for the immobilized antibodies showed similarity to each 
other they were different antibodies produced by different companies.  
In the sandwich assay method, the CEA antigen in the sample was first incubated with the 
anti-CEA detection antibody (Sigma, 5 µg ml
-1
) for 1 hour at 22 
o
C and then was injected on 
the anti-CEA coated sensor surface. Whereas for the indirect capture assay the anti-CEA 
detection antibody coupled with CEA antigen (Ab-Ag complex) was injected on the Rabbit 
anti Mouse (RAM) and mouse IgG coated sensor arrays for the RAM- capture and control 
assays respectively (Figure 2a). Each incubated sample was prepared in 5 µg ml
-1
 BSA and 
the non-specific binding of both 5 µg ml
-1
 anti-CEA detection antibody and 5 µg ml
-1
 BSA 
were recorded before each experiment. The non-specific binding of 5 µg ml
-1
 anti-CEA 
detection on the anti-CEA coating antibodies was recorded as 5.1 ± 5.2 while non-specific 
binding of the 5 µg ml
-1
 BSA on all surface caused only 3 ± 2 RU change (data not shown).  
 
The selected concentration range of CEA samples for the detection was 3-400 ng ml
-1 
and this 
concentration range was studied through two different assay types. The recorded RU changes 
were from 30 to 802 RU in the concentration range of 3-400 ng ml
-1
 CEA and 5 µg ml
-1
 
detection antibody control caused only 3.5 ± 2.7 RU change in the sandwich assay. On the 
other hand, the obtained results were between 13- 430 RU change in the same concentration 
range of CEA antigen for the RAM- capture assay. Moreover, the non-specific binding of 
CEA on the control surface was measured as only 3.5 ± 2.7 RU change. Figure 4B and 4C 
represent the sensorgrams of the sandwich assays and RAM-capture assay respectively. A 
clear difference was observed between the control and active surfaces through both assay 
types. All data were control subtracted. However, the recorded RU changes were found to be 
higher in the sandwich assay (Figure 4 B) when compared to the RAM-capture assay (Figure 
4C) according to the CEA concentration tested. As it is seen in Figure 5 the obtained 
correlation coefficient of the sandwich and RAM-capture assays were 1.00 and 0.99 
respectively with the 3 ng ml 
-1 
detection limit for both assays. 
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Though many different immunological methods have been used to detect various types of 
cancer including radioimmunoassay, enzyme-linked immunosorbent assay, fluorometry, 
chemiluminescence immunoassay they are time-consuming. On the other hand, biosensor 
technologies have provided a real-time, label-free assay approach, gain of time and high 
sensitivity with low detection limits through different type of sensor platforms including 
optical, piezoelectric and capacitive biosensors. Despite of the common use of these sensors 
for the detection of various diseases, there have been very few published papers for human 
CEA protein detection which is a biomarker for common cancer types including lung cancer 
[17] colon cancer [18] and breast cancer [19]. Diagnosis of these cancers at an early stage is 
the most crucial point for an effective therapy and this aim has been achieved at research level 
using a strip biosensor, quartz-crystal microbalance (QCM) and surface plasmon resonance 
(SPR) sensors [20-22]).  
CEA marker was detected by Zeng et al. through a strip biosensor using gold nanoparticles 
(Au-NP) and the molecular recognition between specific antigen and antibody [20]. However, 
the detection limit was at higher level (5 ng ml
-1
) despite the use of Au-NP and more complex 
method when compare to our work. In another publication, antibody-antigen interaction was 
studied to detect human CEA antigen through a quartz crystal microbalance immunosensor 
based on magnetic composite nanoparticle-functionalized biometric interface. By this 
approach, the detection of CEA in the concentration range of 2.5-55 ng ml
-1
 with 0.5 ng ml
-1
 
detection limit was studied and the results were compared with a conventional ELISA 
method. Whilst ELISA needed a long time with many separate steps and labelling, QCM-
based sensor provided approximately same results with reproducible, stable and much faster 
immunoassay [21] which supports the requirement of developing biosensor technologies for 
medical diagnostics.  
Ladd et al investigated the direct detection of CEA autoantibodies for clinical serum samples 
using a SPR biosensor and the results were compared with ELISA that showed the same 
linear trend. Sandwich assay was performed in this study to enhance the sensor signal in 
reverse order when compared with our work (CEA antigen was initially immobilized to the 
surface and polyclonal anti-CEA was then injected to the sensor for measurement) and ~48 ng 
cm
-2
 average binding of antibody was observed [22]. An SPR-based sensor was developed by 
Su and colleagues for the detection of CEA cancer marker with using not only HBS buffer but 
also 10-fold diluted human serum. A 6.2 ng ml
-1
 and 25 ng ml
-1
 CEA could be detected in 
buffer and diluted human serum despite of a complex assay method and the use of various 
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mediator proteins for signal amplification [23]. In this study we used a different approach and 
achieved a detect limit of 3 ng ml
-1
 CEA biomarker in buffer using a simple, reproducible and 
easily applicable method. Future work will concentrate on developing the method further for 
serum analysis.  
 
 
4. Conclusion 
The normal range of CEA in serum for an adult non-smoker is <3 ng ml
-1
 and for a smoker 
<5.0 ng ml
-1
. The concentration of CEA more than 3 ng ml
-1
  in non-smoker and 5 ng ml
-1
  in 
smoker may indicate lung, colon or breast cancer; therefore the detection of this biomarker in 
the range of  3 ng ml
-1
 or lower level is required for early diagnosis of cancer markers. In this 
study homogeneous assay approach with two different methods were implemented to detect 
an important cancer biomarker using SPR sensor. The diagnosis could be measured through 
real-time, label-free technology. Though the detection of cancer markers in real patient 
samples is slightly more challenging than in buffer samples, this technology has provided 
very promising approach.  Here, we have achieved a detection limit of 3 ng ml
-1 
CEA 
concentration with a simple assay design without the use of assay amplifies such as 
nanoparticles which we can implement to enhance the sensitivity further.  Future research will 
be carried out on using human serum to obtain an assay in human body fluids for the 
diagnosis of cancer biomarkers. 
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Table 1: Results of kinetic calculations for CEA biomarker detection in standard and 
optimised assay formats. 
Figure 1: (A) Confirmative assay for the control surface selection with PBS buffer (10mM, 
pH 7.4, 0.0027 M KCl, 0.137 M NaCl). The non-specific binding of (5 µg ml
-1
) BSA to each 
antibody surface (30 µg ml
-1
) (first binding), the non-specific binding of CEA antigen in PBS 
(300 ng ml
-1
) or BSA solution (second and third bindings), the non-specific binding of the 
mixed sample included anti-CEA detection antibody and CEA antigen (last binding). The 
immobilized surfaces: anti-PSA (a), anti-troponin (b), mouse IgG (c). (B) Direct assay 
sensorgram with a 300 ng ml
-1
 concentration of CEA biomarker using the SPR sensor.  CEA 
antigen binding on Abcam’s anti-CEA immobilized (a) and Sigma’s anti-CEA immobilized 
(b, c, d) sensor surfaces.      
Figure 2: Schematic representation of homogenous RAM-capture (a) and sandwich assay (b). 
Figure 3: Optimisation of the incubation time for the CEA antigen with the anti-CEA 
detection antibody. A coating anti-CEA antibody was used on the sensor surface and the 
detection anti-CEA (5 µg ml
-1
) was incubation with the sample CEA (50-400 ng ml
-1
) for 
different incubation time before injection on the sensor chip.  
Figure 4: Immobilisation of anti-CEA coating antibody (red), rabbit anti-mouse (green) and 
mouse IgG (blue) antibodies on the sensor chip surface (A). Sensorgram of the CEA using  
sandwich assay (B), and  RAM-capture assay (C) methods in the concentration range of 3- 
400 ng ml 
-1
. The lowest line represents the control in each assay and the RU change 
gradually increased from the bottom to the top according to the increased CEA concentration. 
Figure 5:  (A) The overall results of sandwich assay, (B) The overall results of RAM-capture 
assay (All shown data is control subtracted). 
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Figure 4 
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Table 1 
Results of kinetic calculations for CEA marker detection with standard and optimised assay 
formats.  
 
Parameters/Assay 
type 
 
Standard assays Optimised RAM-
capture assay 
Optimised Sandwich 
assay 
ka (1/Ms) 8.17 x 10
4 
1x10
3
 6.88 x 10
5 
kd(1/s) 7.29 x 10
-4 
1.46 x 10
-6
 2.09 x 10
-5
 
Rmax 215 RU 428 RU 734 RU 
KD (M) 8.8 x 10
-9
 1.46 x 10
-9
 3.04 x 10
-11 
KA (1/M) 1.13 x 10
8
 9.97 x 10
4 
3.29 x 10
10 
 
 
 
 
 
 
 
 
